Methamphetamine and HIV-1 Infection: Targeted Nanoparticles for Gene Silencing.

描述(由申请人提供)：获得K01奖项将允许申请人通过在快速发展的纳米技术领域进行进一步研究，为获得新知识和技术技能提供受保护的时间，从而成功地过渡到独立研究人员。这项申请的目标是通过将纳米技术与药物滥用在艾滋病毒-1感染中的作用研究相结合，在两个科学学科之间架起一座桥梁。后者是申请者获得国家研究服务奖资助的博士后奖学金的基础。纳米技术方面的额外培训将极大地帮助申请者扩大她的研究方向，将这一新的专门知识应用于开发控制与药物滥用有关的艾滋病毒-1感染的创新方法。在国际知名纳米材料专家Paras Prasad博士的赞助和她的联合赞助人Stanley Schwartz博士的指导下，申请者将接受将纳米技术应用于生物医学应用的教学和实验室培训。施瓦茨博士以研究滥用药物和HIV-1感染而闻名。生物偶联纳米颗粒在利用高分辨率成像技术研究单细胞水平的细胞内过程方面具有巨大的潜力。这项建议将调查有机修饰二氧化硅(ORMOSIL)纳米颗粒作为平台，针对与HIV-1感染相关的特定基因(Galectin-1，蛋白质二硫键异构酶，硫氧还蛋白和过氧化还原蛋白)的平台的有效性，这些基因的表达已被申请人证明受到甲基苯丙胺的调节。ORMOSIL纳米粒子的惰性和无毒性使其在生物医学和临床应用中具有很好的应用前景。跨学科的环境，包括基础科学(化学)和临床(医学)部门，支持这个项目是独一无二的，拥有最先进的设施。布法罗总医院医学系的研究实验室设在布法罗-尼亚加拉医学院，包括生物信息学和生命科学卓越中心和罗斯威尔公园癌症研究所。她还将利用位于布法罗大学主校区的激光、光子学和生物光子学研究所的设施。申请者的职业目标是成为一名独立资助的学术科学家，领导自己的研究实验室。通过将纳米技术、成瘾研究和逆转录病毒学领域联系起来，这些研究可能会产生一种创新和强大的新方法，为药物滥用和艾滋病毒-1感染等严重的公共卫生问题提供进一步的洞察和新的干预措施。

DESCRIPTION (provided by applicant): Receipt of a K01 award will allow the applicant to successfully transition into an independent investigator by providing protected time for the acquistion of new knowledge and technical skills by undertaking further research in the rapidly advancing field of nanotechnology. The objective of this application is to bridge 2 scientific disciplines by integrating nanotechnology with research on the role of drug abuse in HIV-1 infections. The latter was the basis for the applicant's post-doctoral fellowship funded by a National Research Service Award. Additional training in nanotechnology will significantly assist the applicant to expand her research direction by applying this new expertise to the development of innovative methods to control HIV-1 infections associated with drug abuse. Under the sponsorship of Dr. Paras Prasad, an internationally known expert in nanomaterials, and with guidance from her co-sponsor Dr. Stanley Schwartz, known for his research in drugs of abuse and HIV-1 infections, the applicant will receive didactic and laboratory training in applying nanotechnology to biomedical applications. Bioconjugated nanoparticles have great potential for studying intracellular processes at the single-cell level using high-resolution imaging. This proposal will investigate the effectiveness of organically modified silica (ORMOSIL) nanoparticles as a platform to deliver small interfering (siRNA) targeted to specific genes (galectin-1, protein disulfide isomerase, thioredoxin and peroxiredoxin) relevant to HIV-1 infections whose expression has been shown by the applicant to be modulated by methamphetamine. The inertness and non-toxicity of ORMOSIL nanoparticles render them promising materials for biomedical and clinical applications. The interdisciplinary environment, involving both basic science (Chemistry) and clinical (Medicine) departments, supporting this project is unique with state of the art facilities. The research laboratories of the Department of Medicine in the Buffalo General Hospital are on the Buffalo-Niagara Medical Campus including the Center of Excellence in Bioinformatics and Life Sciences and the Roswell Park Cancer Institute. She also will utilize the facilities of the Institute for Lasers, Photonics and Biophotonics on the main campus of the University at Buffalo. The applicant's career goals are to become an independently funded, academic scientist, directing her own research laboratory. By bridging the fields of nanotechnology, addiction research, and retrovirology, these studies may yield an innovative and powerful, new methodology providing further insight into and new interventions for the serious public health issues of drug abuse and HIV-1 infections.